Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Geltrex-based protocol for the differentiation of rat adipose tissue-derived mesenchymal stem cells into insulin-producing cells: in vitro and in vivo considerations.

Ahmed HH., Mahmoud NS., Aglan HA.

Animal Study on Systemic / IV, published in Naunyn Schmiedebergs Arch Pharmacol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Naunyn Schmiedebergs Arch Pharmacol (2025)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
41460315
DOI
10.1007/s00210-025-04902-5

Abstract (original English)

Diabetes mellitus (DM) is a chronic illness manifested by uncontrolled glycemic levels. The present investigation was designed to explore the role of Geltrex, integrated with inducing factors, in driving the differentiation of rat adipose tissue-extracted mesenchymal stem cells (ADSCs) into efficient insulin-producing cells (IPCs) and to appraise the curative effect of the generated IPCs against type I DM rat model elicited by intraperitoneal injection of streptozotocin. ADSCs were harvested, characterized, and stimulated to differentiate into IPCs using a Geltrex matrix supplemented by a mixture of growth factors and other differentiation-inducing factors. The identity of the resultant IPCs was affirmed by measuring the expression levels of IPC-related genes and an insulin secretion assay. Then, the therapeutic efficacy of the well-characterized IPCs was assessed via implantation in a diabetic rat model. The Geltrex-based differentiation protocol successfully generated functional IPCs displaying upregulated levels of pancreatic endocrine genes. Moreover, the PKH-26 staining monitored the engraftment of IPCs into the pancreas of the treated rats. Additionally, IPC transplantation in diabetic rats elicited a significant enhancement in metabolic indices and motivated a significant overexpression of the pancreatic-specific genes. The therapeutic impact of the inoculated IPCs was f

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMesenchymal Stem CellsCell DifferentiationDiabetes Mellitus, ExperimentalAdipose TissueMaleInsulin-Secreting CellsMesenchymal Stem Cell TransplantationInsulinRats

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research